Company Encyclopedia
View More
name
Axogen
AXGN.US
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons.
1.407 T
AXGN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking26/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-1.90%D
    • Profit Margin-0.98%D
    • Gross Margin76.55%A
  • Growth ScoreA
    • Revenue YoY18.72%B
    • Net Profit YoY85.34%A
    • Total Assets YoY12.72%B
    • Net Assets YoY21.53%A
  • Cash ScoreC
    • Cash Flow Margin-10238.87%E
    • OCF YoY18.72%B
  • Operating ScoreA
    • Turnover1.05A
  • Debt ScoreC
    • Gearing Ratio44.18%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Axogen Inc. Raises CFO Lindsey Hartley’s Salary and Bonus Target

    Axogen Inc. has approved new compensation terms for CFO Lindsey Hartley, effective January 1, 2026. Her annual base salary will increase by 7%, and her target bonus opportunity will rise from 50% to 60% of her annual base salary. Hartley also signed an amended confidentiality and non-competition agreement. Other employment terms remain unchanged.

    Reuters·
    US
    AXGN
    +1.42%
    Reuters·
    US
    AXGN
    +1.42%

    Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment

    Axogen Inc. achieved a 52-week high after the FDA approved its Avance Nerve Graft for treating peripheral nerve discontinuities. The graft uses processed human nerve tissue from cadavers, avoiding the need for a second surgical site. Axogen's Q3 revenue rose 23.5% to $60.1 million, surpassing expectations. The company raised 2025 revenue guidance and expects positive net cash flow for the year. Shares rose 18.78% to $31.01.

    fidelity·
    US
    AXGN
    +1.42%
    fidelity·
    US
    AXGN
    +1.42%

    Axogen shares are trading higher after the FDA approved its biologics license application for AVANCE for peripheral nerve discontinuities.

    benzinga_article·
    US
    AXGN
    +1.42%
    benzinga_article·
    US
    AXGN
    +1.42%

    FDA approves Axogen's BLA for AVANCE® (acellular nerve allograft-arwx). Dec. 03, 2025: Axogen, Inc. announces FDA approval.

    In Alachua, Florida and Tampa, Florida on December 3, 2025, Axogen, Inc. (NASDAQ: AXGN), a prominent company in the advancement and promotion of cutting-edge surgical technologies for revitalizing peripheral nerve function, revealed that the U.S. Food and Drug Administration (FDA) has given the green light to the Biologics License Application (BLA) for AVANCE® (acellular nerve allograft-arwx).

    Unusual Whales·
    US
    AXGN
    +1.42%
    Unusual Whales·
    US
    AXGN
    +1.42%

    FDA Approves Axogen's Biologics License Application for Avance Nerve Allograft

    Axogen Inc. has received FDA approval for its Biologics License Application for AVANCE® nerve allograft, now classified as a biologic for treating nerve discontinuities. Approved under the Accelerated Approval pathway, continued approval depends on confirmatory studies. Commercial availability is expected early Q2 2026.

    Reuters·
    US
    AXGN
    +1.42%
    Reuters·
    US
    AXGN
    +1.42%
    © 2025 Longbridge｜Disclaimer